Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics - An immunohistochemical and RT-PCR study by Rodriguez, FJ et al.
Galectin-3 Expression is Ubiquitous in Tumors of the
Sellar Region, Nervous System, and Mimics
An Immunohistochemical and RT-PCR Study
Fausto J. Rodriguez, MD,* Bernd W. Scheithauer, MD,* Federico Roncaroli, MD,w
Ana I. Silva, MD,z Kalman Kovacs, MD, PhD,y Daniel J. Brat, MD, PhD,J and Long Jin, MD*
Abstract: Galectin-3 expression has been reported in spindle cell
oncocytoma, certain pituitary adenoma subtypes, astrocytomas,
oligodendrogliomas, and meningiomas. We evaluated galectin-3
protein expression by immunohistochemistry in 201 cases of a
variety of nervous system and sellar tumors, as well as mRNA
expression by reverse transcription-polymerase chain reaction in
formalin-fixed paraffin-embedded tissue in a subset (20 cases).
Immunohistochemical results were evaluated in a semiquantita-
tive fashion on a 4-tiered scale (0 to 3). Strong (3+)
immunoreactivity was seen in most of the cases (61%), followed
by 2+(22%), and 1+(13%) staining. Only 4% of the lesions
studied were immunonegative. Galectin-3 mRNA was present in
15 of the 18 cases (83%) in which reverse transcription-
polymerase chain reaction was successful. Significant differences
in protein expression were noted in the following 2 settings:
specific meningioma subtypes (P=0.004, Fisher exact test)
wherein clear cell meningioma demonstrated weak protein
expression when compared with other meningioma variants.
No significant difference was noted with respect to World
Health Organization grade. Galectin-3 was also strongly
expressed in benign nerve sheath tumors but only moderately
expressed in malignant peripheral nerve sheath tumors
(P=0.0009, Fisher exact test). Although galectin-3 positivity
is a key feature of the immunophenotype of spindle cell
oncocytoma, its consistent expression in other morphologically
similar tumors (meningioma, pituicytoma, nerve sheath tumors,
granular cell tumor, metastases) makes it of little use in the
differential diagnosis of sellar region tumors, a setting in which it
should be discouraged. Diagnostic uses of this marker may be
limited to specific settings, including some meningioma subtypes
and nerve sheath tumors.
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Galectin-3 is a b-galactoside binding protein recentlyfound to be expressed in a variety of endocrine
tumors, including papillary thyroid carcinoma33 and
adenohypophyseal cell tumors,24,32 in particular prolactin
and adrenocorticotropic hormone (ACTH) producing
adenomas and carcinomas. This has engendered interest
in the role of this molecule in the development and
progression of endocrine tumors. The immunoexpression
of galectin-3 as an aid in diagnosis and tumor grading has
also been studied in meningiomas7,12,13 and in localized
and infiltrative gliomas.4,8,20,30
Among sellar lesions, spindle cell oncocytoma
(SCO) is a recently described tumor thought to originate
from folliculostellate cells25 on the basis of uniform
galectin-3, epithelial membrane antigen (EMA), and
S-100 protein immunoreactivity and on the negativity
for other markers, including pituitary hormones, glial
fibrillary acidic protein, and synaptophysin. The differ-
ential diagnosis of SCO is varied. Indeed, a variety of
primary and metastatic tumors may mimic it. As a result,
galectin-3 expression in this considerable spectrum and its
mimics deserves attention.
The goal of this study was 2-fold: first, to evaluate
galectin-3 expression and its role in the differential
diagnosis of primary and secondary, nonendocrine
tumors affecting the central and peripheral nervous
system, including some rare entities; second, to explore
the diagnostic utility of this marker in the sellar region,
specifically in morphologic mimics of SCO. Galectin-3
expression in endocrine tumors of the sellar region has
been addressed elsewhere.14,24–27
MATERIALS AND METHODS
The files of Mayo Clinic Tissue Registry (Rochester,
MN) and Charing Cross Hospital (Imperial College,
London, England) were searched for representative
primary and metastatic tumors of the nervous system
and sellar region, as well as neoplasms included in
the differential diagnosis of SCO. Histologic types and
locations of the lesions are summarized in Table 1.
Immunohistochemistry
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TABLE 1. Galectin-3 Immunoreactivity by Tumor Type
Immunohistochemical Score N (%)
Histology 0 1 2 3
Meningiomas
Fibrous — — — 6
Meningothelial — — 3 7
Transitional — — 2 1
Clear cell — 4 1 1
Secretory — 1 — 1
Angiomatous — — — 1
Microcystic — — 1 1
Papillary/rhabdoid — 1 1 —
Chordoid — — — 1
Subtotal 6 (18%) 8 (24%) 19 (58%)
Reactivity by WHO Grade I — 1 4 9
Grade II — 4 3 6
Grade III — 1 1 4
Nerve sheath tumor
Schwannoma conventional — — 2 5
Cellular — — — 8
MPNST — 1 5 2
Conventional neurofibroma — — — 7
Atypical neurofibroma — — — 1
Cellular neurofibroma — — — 1
Subtotal 1 (3%) 7 (22%) 24 (75%)
Sarcomas
Synovial sarcoma (sellar) 1 (epithelial element; score of
2+ in spindle element)
Synovial sarcoma (soft tissue) 1 1
Metastatic leiomyosarcoma to brain 1
Leiomyosarcoma (soft tissue) 1 3
Fibrosarcoma (brain) 1
Fibrosarcoma (soft tissue) 2 1
Pleomorphic spindle cell sarcoma (brain) 2
Pleomorphic spindle cell sarcoma (soft tissue) 1 2
Metastatic myxoid chondrosarcoma to brain 1
Subtotal 1 (6%) 6 (33%) 5 (28%) 7 (39%)
Hemangiopericytoma of dura
Grade II 1 1




Subtotal 2 (18%) 4 (36%) 2 (18%) 3 (28%)







Subtotal 1 (5%) 4 (21%) 14 (74%)
Choroid Plexus Tumors
Papilloma 1 2 1
Atypical papilloma 1
Carcinoma 1 2
Subtotal 1 (13%) 4 (50%) 2 (25%) 1 (13%)
Melanoma involving the CNS 1 (11%) 1 (11%) 7 (78%)
Ependymoma
WHO Grade II — 2 1 1
WHO Grade III 1 — — 2
Subtotal 1 (14%) 2 (29%) 1 (14%) 3 (43%)
Granular cell tumor of pituitary 4 (100%)
Pituicytoma 1 (25%) 3 (75%)
Other
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(Novocastra, Burlingame, CA; clone 9C4, dilution 1:50).
Five-micron sections from representative blocks were
deparaffinized in xylene and dehydrated in serial alcohols.
Pretreatment was performed in 1-mM ethylenediamine
tetra-acetate solution, pH 8.0, at 981C for 30 minutes.
This was followed by peroxidase block and incubation
with the primary antibody for 30 minutes, and 20 minutes
in the Envision+Dual Link detection system on a Dako
autostainer. Diaminobenzidine served as the chromogen.
Semiquantitative scoring of the reaction was performed
by 2 observers (F.J.R. and B.W.S.) on a 4-tiered scale
(0=absent, 1=weak staining intensity to moderate
staining in <10% of cells, 2=moderate staining in less
than 50% of cells, 3=moderate-to-strong intensity
staining in greater than 50% of cells).
Reverse Transcription-Polymerase
Chain Reaction
We also performed reverse transcription-polymer-
ase chain reaction (RT-PCR) to confirm expression of
galectin-3 mRNA and see if it correlated with detection
of the protein by immunohistochemistry. Total RNA was
extracted from formalin-fixed paraffin-embedded tissue
sections and used for RT-PCR in a subset of cases
(n=20) for which adequate material was available from
the same block used for immunohistochemical analyses.
Only blocks composed almost entirely (>95%) of tumor
cells were included. The RNA concentration was mea-
sured with a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies Inc, Wilmington, DE). Total
RNA (400 ng) was used for reverse transcription in a
20 uL of total volume, using reagents from the Strata-
Script First-Strand Synthesis System kit (Stratagene,
La Jolla, CA) following the manufacturer’s instructions.
PCR primers used for galectin-3 transcription included:
50-CAA CTG CCA CCG GAG CCT A (forward) and
50-CTG TTT GCA TTG GGC TTC ACC (reverse), the
PCR product size being 148 base pairs (GenBank access
no.: NM_000291). Phosphoglycerate kinase served as a
loading gel control (189-bp product size). Amplification
was performed in a 25-uL final reaction volume contain-
ing 2 uL of RT product as template DNA, 1x PCR buffer,
2.5-mM MgCl2 0.2mM of each deoxynucleotide, 0.3 uM
of forward and reverse primers, and 1.0U of Taq DNA
polymerase (Invitrogen, Carlsbad, CA). Programmable
temperature cycling (GeneAmp PCR System 9700 ther-
mal cycler, PE Applied Biosystems, Foster City, CA) was
performed using the following schedule: initial denatura-
tion at 951C, for 2 minutes, followed by 40 cycles of
denaturation at 941C for 30 seconds, annealing at 551C
for 30 seconds, extension at 721C for 1 minute, and final
extension at 721C for 10 minutes. Formalin-fixed paraffin-
embedded tissue sections from a papillary thyroid
carcinoma served as a positive control, and omission of
reverse transcriptase in the RT reaction as a negative
control.
Statistics
Statistical analyses were performed using contin-
gency tables and the Fisher exact test for comparing




Results of immunohistochemical scoring are sum-
marized by tumor type in Table 1, representative
illustrations being shown in Figures 1 to 3. Reactivity
was generally cytoplasmic and sometimes nuclear, espe-
cially in the tumors showing strong galectin-3 expression.
In summary, strong (3+) immunoreactivity was noted in
most of the specimens (61%), followed by 2+ (22%), and
1+ (13%). Only 4% of the cases were immunonegative,
including 2 hemangiopericytomas of the dura, and 1 each
metastatic carcinoma of the prostate, choroid plexus
carcinoma, grade III ependymoma, glioblastoma, leio-
myosarcoma, and Langerhans cell histiocytosis. Mimics
of SCO, including granular cell tumor and pituicytoma
were strongly immunoreactive (100% and 75% of cases,
respectively). Other tumors demonstrating 3+ immuno-
reactivity included melanoma (78%), nerve sheath tumors
(75%), metastatic nonsmall cell carcinoma (74%), and
meningiomas (58%) (Table 1). Sarcomas showed variable
TABLE 1. (continued)
Immunohistochemical Score N (%)
Histology 0 1 2 3




Glioblastoma 1 2 6
Langerhans cell histiocytosis 1 1 — 2
Chordoma 5
Total 8 (4%) 27 (13%) 43 (22%) 123 (61%)
CNS indicates central nervous system; DIG, desmoplastic infantile ganglioglioma; MPNST, malignant peripheral nerve sheath tumor; NOS, not otherwise specified;
PXA, pleomorphic xanthoastrocytoma; SEGA, subependymal giant cell astrocytoma; WHO, World Health Organization.
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FIGURE 1. Galectin-3 immunoreactivity in dura-based neoplasms. All cases of fibrous meningioma (A) demonstrated strong
diffuse immunoreactivity (B). Conversely, clear cell meningiomas (C) showed limited staining of a minority of tumor cells and
vessels (D). One example of hemangiopericytoma, characterized by dense cellularity and branching vessels, (E) showing no
immunostaining for galectin-3. The conspicuous vascularity was a useful internal positive control (F).
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FIGURE 2. Galectin-3 immunoreactivity in nerve sheath tumors. Neurofibroma with its benign, wavy nuclei and delicate
collagenous matrix (A) showing diffuse immunoreactivity (B). All cellular schwannomas (C) were similarly positive (D). Malignant
peripheral nerve sheath tumors (E) in general demonstrated weaker staining than the benign tumors (F).
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FIGURE 3. Galectin-3 immunoreactivity in the differential diagnosis of spindle cell oncocytoma. All granular cell tumors (A) were
diffusely and strongly immunoreactive (B). The majority of pituicytomas were also strongly immunoreactive (C), although
1 tumor showed only moderate staining (D). One rare example of primary synovial sarcoma of the sellar region showing
characteristic, biphasic morphology (E) and staining of both components, immunoreactivity being stronger in the glandular than
in spindle cells (F).
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immunoreactivity, but with an overall lower frequency of
3+ staining (39%). Although all leiomyosarcomas tested
showed 0 to 1+ immunoreactivity, this divergence did
not reach statistical significance when compared with
other sarcomas (P=0.07).
Meningiomas demonstrated differences in immu-
noreactivity among its subtypes (P=0.004, Fisher exact
test). Weak immunoreactivity (1+) was limited to clear
cell (4 of 6 cases), secretory (1 of 2), and papillary/rhab-
doid types (1 of 2). In the category of nerve sheath
tumors, 6 of 8 malignant examples demonstrated 1–2+
immunoreactivity versus 2 of 24 benign nerve sheath
tumors (P=0.0009); the remaining tumors demonstrated
3+ reactivity. When comparing chordomas versus
chordoid gliomas, all chordomas (5 of 5) demonstrated
3+ staining compared with similar reactivity in 2 of 6
chordoid gliomas (P=0.046). In the choroid plexus,
tumor group 3 of 3 carcinomas and a single atypical
papilloma showed absent to 1+ immunoreactivity as
compared with 2-3+ staining in 3 of 4 papillomas; this
difference showed only a trend toward statistical sig-
nificance (P=0.07).
RT-PCR
The results of RT-PCR studies are illustrated in
Figure 4. Only 2 failures were encountered based on an
absent or weak band for phosphoglycerate kinase (results
not shown). Positive and negative controls reacted
appropriately. Galectin-3 mRNA was identified in 15
(83%) of the 18 cases tested; the majority demonstrated
variable immunoreactivity, including 3+ (n=8), 2+
(n=2), and 1+ (n=4). One each of metastatic
melanoma, ependymoma, and hemangiopericytoma were
negative. The hemangiopericytoma and melanoma sam-
ples negative by RT-PCR were, nonetheless, immuno-
positive for galectin-3, reactivity in the melanoma being
patchy and not present in all fields. In a third case,
another hemangiopericytoma, galectin-3 mRNA was
identified by RT-PCR, but not by immunohistochemistry
despite an adequate internal vessel-positive control. The
single grade III ependymoma negative for galectin-3
mRNA by RT-PCR was also immunonegative for the
protein.
DISCUSSION
Galectins are a sizable family of lectin proteins that
bind b-galactoside sugars.1,22 Galectin-3 has been identi-
fied in a variety of mammals, including humans, dogs,
rats, and mice. Weighing 31 kd,19 it features a carbohy-
drate binding domain, a short N-terminal domain, and a
proline, glycine, and tyrosine-rich domain. Galectin-3
is involved in a variety of basic cell processes, including
growth, adhesion, differentiation, and regulation of
apoptosis. Furthermore, it seems to play a role in tumor
progression.24,35
In the past decade, there has been increasing interest
in the role of galectin-3 in human neoplasia. High levels
of expression of this molecule have been observed in a
variety of tumors, including colon,5 lung,18 salivary
gland,31,34 thyroid,9,33 and uterus.28 In the pituitary,
galectin-3 has been found to be expressed in normal
prolactin, ACTH, and folliculostellate cells.24 In pituitary
neoplasms, galectin-3 is expressed in endocrinologically
functioning prolactin and ACTH adenomas, but not in
others.14,24 Higher levels of expression have been also
identified in prolactin and ACTH carcinomas.24,27 What
follows is a discussion of findings in various other tumor
groups.
Gliomas
Galectin-3 is expressed in a variety of cell types
within the nervous system, including neurons of dorsal
root ganglion neurons, microglial cells, and macrophages
in reactive processes.10 There have been several reports of
galectin-3 expression in tumors of the central nervous
system, both primary and metastatic.4 These include
diffusely infiltrative gliomas,4,6,8,10,20,30 in which some
authors have reported an association between its expres-
sion and increasing World Health Organization (WHO)
grade in astrocytic tumors.4 Yet other authors have found
that galactin-3 expression varies among different clones of
a given tumor10 and may also be expressed by non-
neoplastic components within the tumor, including
macrophages, microglia, and endothelial cells.30 Galec-
tin-3 expression has also been reported in glioma cell
lines.17 Other investigators have explored galectin-3
expression in glioma invasion, where the biology of this
molecule may be more complex and not completely
understood. For example, galectin-3 may be cleaved
by several metalloproteinases19,21 and the secreted form
and/or cleaved products may partially account for
invasive behavior in cell lines.19
FIGURE 4. Galectin-3 mRNA is ubiquitously expressed in
nervous system tumors and in mimics of SCO as demonstrated
by reverse transcription-polymerase chain reaction. A 2%
agarose gel stained with ethidium bromide and viewed under
ultraviolet light demonstrates a galectin-3, 148-bp product
in most tumors tested (top lane). Phosphoglycerate
kinase served as a loading control (bottom lane). Case
numbers correspond to the following tumor types: 1–menin-
gothelial meningioma, 2–hemangiopericytoma, 3–schwanno-
ma, 4–fibrous meningioma, 5–anaplastic ependymoma,
6–hemangiopericytoma, 7–metastatic melanoma, 8–schwan-
noma, 9–leiomyosarcoma, 10–neurofibroma, 11–subependy-
mal giant cell astrocytoma, 12–solitary fibrous tumor,
13–gliosarcoma, 14–leiomyosarcoma, 15–gliosarcoma, 16–ma-
lignant peripheral nerve sheath tumor, 17–metastatic carcino-
ma, 18–chordoma. A papillary thyroid carcinoma was used as
positive control (+), and omission of reverse transcriptase was
used as negative control ( ). Two cases represented reverse
transcription-polymerase chain reaction failures owing to an
absent/weak phosphoglycerate kinase band (not shown).
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SCO
The SCO is a recently described, unique tumor of
the sellar region characterized by immunopositivity for
S-100 protein, EMA, vimentin, and galectin-3.25 Its
behavior resembles that of WHO grade I meningiomas
and is generally favorable. Recurrence has been docu-
mented in 1 bona fide example, that being case 1 in the
series of Kloub et al.16 The differential diagnosis of SCO
includes a variety of tumors featuring spindle and
epithelioid cells, ones either primary in the sellar region
or involving it by direct extension or metastasis. These
include meningioma, especially of the fibrous type,
hemangiopericytoma, pituicytoma, schwannoma, solitary
fibrous tumor, astrocytomas, melanoma, carcinoma, and
sarcoma. Although relative absence of marked cytologic
malignancy should aid in the distinction of SCO from
most metastatic tumors, SCO may show considerable,
often focal cellular and nuclear pleomorphism,25,29 a
feature of unknown significance.
It is of note that galectin-3 immunoreactivity has
been described in tumors mimicking SCO. For example,
Das and colleagues7 found immunoreactivity in the
majority of meningiomas; all their examples of the
transitional subtype showing moderate to strong staining.
Interestingly, our current study revealed strong, diffuse
galectin-3 immunoreactivity in a wide variety of tumors in
the differential diagnosis of SCO, including all granular
cell tumors, most pituicytomas and all fibrous meningio-
mas. Even Langerhans cell histiocytosis was strongly
immunoreactive in 2 of 4 cases tested.
Pituicytoma in particular is an important tumor in
the differential diagnosis with SCO, given its spindle cell
morphology and S-100 immunoreactivity. Although this
tumor is presumably glial in origin, glial fibrillary acidic
protein immunoreactivity may be weak or entirely
absent.3 However, EMA is generally negative, and
ultrastructurally, the tumor lacks conspicuous mitochon-
drial accumulation unlike SCO. Galectin-3, as confirmed
by our current study, may be expressed by this tumor and
should not be used to distinguish it from SCO. As it is
true of most challenging differential diagnoses in surgical
pathology, a judicious panel of immunostains is of
optimal benefit.
Meningiomas
It is of interest that previous authors explored a
possible association between low-level galectin-3 expres-
sion and histologic atypia in meningiomas. Hancq et al13
described strong expression of galectin-3 binding ligands
in 64% of benign (WHO grade I) meningiomas, but
found it only in 29% of atypical (grade II) examples.
However, they found no difference in galectin-3 staining
in reactive tumors within the 2 groups. The same was true
of reactivity in another study of recurrent versus non-
recurrent WHO grade I meningiomas.12 Das and
colleagues7 also found moderate-to-strong galectin-3
immunoreactivity in 90% of WHO grade I meningiomas,
full 100% of the transitional subtype being positive. Our
study reinforces these findings, as there was no statisti-
cally significant difference in galectin-3 immunoreactivity
by WHO grade. Nonetheless, clear cell meningiomas
showed weaker expression than other histologic variants
or the group as a whole.
Nerve Sheath Tumors
Also of interest is our finding of consistent galectin-
3 immunoreactivity in all nerve sheath tumors and
galectin-3 mRNA expression in 4 of the 4 examples
tested. Similar findings were reported in the study of
Bigotti et al,2 who found strong immunoreactivity in
all nerve sheath tumors tested, benign and malignant.
Galectin-3 staining was also found in non-neoplastic
Schwann cells in a peripheral nerve injury model.23 Of
note, in our study was the finding of decreased
immunoexpression in malignant peripheral nerve sheath
tumors as compared with the benign nerve sheath tumors,
the difference being statistically significant and perhaps
useful in differential diagnosis.
Sarcomas
In the present study, we found variable galectin-3
staining in sarcomas, there being only a trend toward
weaker staining in leiomyosarcomas. Bigotti and collea-
gues,2 in a study of galectin-3 expression in soft tissue
tumors and pseudotumors similarly showed that most
lesions express the marker, although smooth and skeletal
muscle tumors do so to a lesser extent. Conversely,
Schwartz et al28 in a study of smooth muscle tumors of
the uterus demonstrated an increase in galectin-3 expres-
sion and binding sites in the malignant subgroup. Lastly,
our study of chordomas demonstrated strong diffuse
expression in all cases. Similar findings were previously
reported.11,15 Interestingly, galectin-3 expression in the
developing notochord, remnants of which are presumed
to give rise to chordomas, increases with advanced
gestational age.11
SUMMARY
Our study demonstrated that galectin-3 was identifi-
able by immunohistochemistry in a wide variety of
tumors of the sellar region and nervous system, including
ones that enter in the differential diagnosis of SCO. In
addition, galectin-3 mRNA was identified in most of the
cases tested, although discordant immunohistochemistry
and mRNA expression results were observed in 3 cases
out of the 18 tested. Prior studies have also generally
shown good correlation between galectin-3 protein and
mRNA expression, although the concordance is not
necessarily perfect.9 The reason for minor discrepancies
may be multifactorial. For example, 1 melanoma case was
negative by RT-PCR and although it showed immuno-
positivity for galectin-3, the latter was patchy, many
microscopic fields lacking its expression. Therefore, the
discrepant results may be explained in part by tumor
heterogeneity. In addition, our study used a monoclonal
antibody directed against galectin-3, thus differences in
the sequences recognized by the RT-PCR primers and the
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protein epitope demonstrated by the antigalectin-3 anti-
body may be an alternative explanation.
In conclusion, moderate-to-strong expression of
galectin-3 is seen in a variety of tumor types, both in
the central and peripheral nervous system, and also in the
sellar region. Although this marker is of potential use in
the differential diagnosis of tumor groups and is a requisite
to the diagnosis of SCO, we discourage its use in differential
diagnosis of morphologically similar tumors, and recom-
mend instead an immunohistochemical panel in combina-
tion with a careful morphologic assessment.
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